Stewart 1969.

Methods	Allocation: randomly assigned, no further information. Blindness: double (identical capsules). Design: crossover. Duration: 14 days (washout) + 28 days (1st placebo period) + 56 days (first drug period) + 28 days (2nd placebo period) + 56 days (2nd drug period). Analysis: intention‐to‐treat. Country: Canada.
Participants	Diagnosis: schizophrenia, no further details. N=50. Age: range 33‐59 years, mean 48.6 years. Sex: M 17, F 8 each group. Setting: hospital. History: "chronic" (hospitalised from 3‐37 years); free of epilepsy, chronic brain syndrome and arterioesclerosis and none lobotomized.
Interventions	1. Trifluoperazine: range 4‐16 mg/day. N=25. 2. Haloperidol: range 4‐16 mg/day. N=25.
Outcomes	Global state: (overall Improvement). Unable to use ‐ Mental state: (BPRS; IMPS; Rockland‐Pollin Scale). Side effects. Behaviour: (MACC ‐ modified). Laboratory tests. Vital signs.
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear